Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells 3,051 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,051 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $7.82, for a total transaction of $23,858.82. Following the completion of the sale, the chief technology officer directly owned 1,920,804 shares in the company, valued at approximately $15,020,687.28. This trade represents a 0.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Badawi also recently made the following trade(s):

• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The stock was sold at an average price of $7.48, for a total transaction of $27,638.60.
• On Friday, January 2nd, David Badawi sold 2,914 shares of Sight Sciences stock. The shares were sold at an average price of $7.43, for a total transaction of $21,651.02.

Sight Sciences Stock Down 3.1%

Shares of SGHT traded down $0.24 during midday trading on Tuesday, reaching $7.47. The stock had a trading volume of 197,717 shares, compared to its average volume of 290,394. The company has a market cap of $394.94 million, a price-to-earnings ratio of -8.30 and a beta of 2.42. The company’s fifty day simple moving average is $7.52 and its two-hundred day simple moving average is $5.13. Sight Sciences, Inc. has a 1-year low of $2.03 and a 1-year high of $9.24. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93.

Sight Sciences (NASDAQ:SGHT) last issued its earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The firm had revenue of $12.54 million for the quarter. Equities research analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Key Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Piper Sandler upgraded Sight Sciences to Overweight (from Neutral), a buy-side analyst upgrade that can attract investor interest and buying momentum. Piper Sandler upgrade
• Neutral Sentiment: Despite recent sales, insiders still hold large positions — CEO Paul Badawi (~5.9M shares) and CTO David Badawi (~1.9M shares) retain substantial ownership, which can indicate alignment with long-term value even as they trim stakes. Insider ownership filing
• Negative Sentiment: Clustered insider selling by executives — CEO Paul Badawi, CTO David Badawi, CFO James Rodberg, EVP Brenton Taylor and insider Jeremy Hayden — over Jan. 2–6. Combined disclosed sales total roughly $0.48M across these transactions; each sale was a small percentage (<1%) of the seller’s holdings but the concentrated timing can create downward pressure on the stock. See CEO / executive filings. CEO sale filing CTO sale filing Other insider filings

Analyst Ratings Changes

Several equities research analysts recently weighed in on SGHT shares. Morgan Stanley boosted their target price on Sight Sciences from $6.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Wall Street Zen upgraded shares of Sight Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. Piper Sandler set a $9.00 price target on shares of Sight Sciences in a research report on Monday. Citigroup increased their price target on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Finally, Raymond James Financial set a $9.00 price objective on shares of Sight Sciences in a research note on Monday. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Sight Sciences has an average rating of “Hold” and a consensus target price of $8.30.

Institutional Investors Weigh In On Sight Sciences

Large investors have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new position in Sight Sciences in the 1st quarter valued at $128,000. Acadian Asset Management LLC lifted its stake in shares of Sight Sciences by 127.7% in the 1st quarter. Acadian Asset Management LLC now owns 432,541 shares of the company’s stock worth $1,033,000 after acquiring an additional 242,559 shares during the period. Strs Ohio purchased a new stake in shares of Sight Sciences in the first quarter valued at about $158,000. Rhumbline Advisers increased its stake in shares of Sight Sciences by 9.5% during the first quarter. Rhumbline Advisers now owns 49,797 shares of the company’s stock worth $120,000 after acquiring an additional 4,319 shares during the period. Finally, KCK LTD. purchased a new position in Sight Sciences during the second quarter worth about $18,069,000. Hedge funds and other institutional investors own 55.51% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.